vs

Side-by-side financial comparison of PTC THERAPEUTICS, INC. (PTCT) and Udemy, Inc. (UDMY). Click either name above to swap in a different company.

Udemy, Inc. is the larger business by last-quarter revenue ($194.0M vs $164.7M, roughly 1.2× PTC THERAPEUTICS, INC.). Udemy, Inc. runs the higher net margin — -1.2% vs -82.0%, a 80.8% gap on every dollar of revenue. On growth, Udemy, Inc. posted the faster year-over-year revenue change (-3.0% vs -22.7%). Udemy, Inc. produced more free cash flow last quarter ($15.0M vs $-36.6M). Over the past eight quarters, Udemy, Inc.'s revenue compounded faster (-0.7% CAGR vs -11.5%).

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.

Udemy is a US-based education technology company. Founded as a massive open online course (MOOC) provider in 2010 by Eren Bali, Gagan Biyani, and Oktay Caglar; the company is based in San Francisco, California, with offices in the United States, Australia, India, Ireland, Mexico and Turkey. Its education platform allows both the creation and sharing of online courses. By early 2025, Udemy claimed to have millions of individual users. Courses are typically video-based and on-demand.

PTCT vs UDMY — Head-to-Head

Bigger by revenue
UDMY
UDMY
1.2× larger
UDMY
$194.0M
$164.7M
PTCT
Growing faster (revenue YoY)
UDMY
UDMY
+19.8% gap
UDMY
-3.0%
-22.7%
PTCT
Higher net margin
UDMY
UDMY
80.8% more per $
UDMY
-1.2%
-82.0%
PTCT
More free cash flow
UDMY
UDMY
$51.6M more FCF
UDMY
$15.0M
$-36.6M
PTCT
Faster 2-yr revenue CAGR
UDMY
UDMY
Annualised
UDMY
-0.7%
-11.5%
PTCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PTCT
PTCT
UDMY
UDMY
Revenue
$164.7M
$194.0M
Net Profit
$-135.0M
$-2.3M
Gross Margin
66.0%
Operating Margin
-43.3%
-1.8%
Net Margin
-82.0%
-1.2%
Revenue YoY
-22.7%
-3.0%
Net Profit YoY
-104.8%
76.4%
EPS (diluted)
$-1.63
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PTCT
PTCT
UDMY
UDMY
Q4 25
$164.7M
$194.0M
Q3 25
$211.0M
$195.7M
Q2 25
$178.9M
$199.9M
Q1 25
$1.2B
$200.3M
Q4 24
$213.2M
$199.9M
Q3 24
$196.8M
$195.4M
Q2 24
$186.7M
$194.4M
Q1 24
$210.1M
$196.8M
Net Profit
PTCT
PTCT
UDMY
UDMY
Q4 25
$-135.0M
$-2.3M
Q3 25
$15.9M
$1.6M
Q2 25
$-64.8M
$6.3M
Q1 25
$866.6M
$-1.8M
Q4 24
$-65.9M
$-9.9M
Q3 24
$-106.7M
$-25.3M
Q2 24
$-99.2M
$-31.8M
Q1 24
$-91.6M
$-18.3M
Gross Margin
PTCT
PTCT
UDMY
UDMY
Q4 25
66.0%
Q3 25
65.9%
Q2 25
66.1%
Q1 25
64.6%
Q4 24
63.6%
Q3 24
63.0%
Q2 24
62.3%
Q1 24
61.2%
Operating Margin
PTCT
PTCT
UDMY
UDMY
Q4 25
-43.3%
-1.8%
Q3 25
1.4%
-0.1%
Q2 25
-19.5%
2.0%
Q1 25
82.5%
-2.2%
Q4 24
-76.2%
-5.8%
Q3 24
-27.7%
-15.1%
Q2 24
-21.5%
-13.1%
Q1 24
-21.6%
-11.5%
Net Margin
PTCT
PTCT
UDMY
UDMY
Q4 25
-82.0%
-1.2%
Q3 25
7.5%
0.8%
Q2 25
-36.3%
3.1%
Q1 25
73.7%
-0.9%
Q4 24
-30.9%
-4.9%
Q3 24
-54.2%
-12.9%
Q2 24
-53.1%
-16.4%
Q1 24
-43.6%
-9.3%
EPS (diluted)
PTCT
PTCT
UDMY
UDMY
Q4 25
$-1.63
$-0.01
Q3 25
$0.20
$0.01
Q2 25
$-0.83
$0.04
Q1 25
$10.04
$-0.01
Q4 24
$-0.85
$-0.06
Q3 24
$-1.39
$-0.17
Q2 24
$-1.29
$-0.21
Q1 24
$-1.20
$-0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PTCT
PTCT
UDMY
UDMY
Cash + ST InvestmentsLiquidity on hand
$1.9B
$358.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$-205.3M
$210.5M
Total Assets
$2.9B
$617.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PTCT
PTCT
UDMY
UDMY
Q4 25
$1.9B
$358.7M
Q3 25
$1.7B
$371.2M
Q2 25
$2.0B
$392.0M
Q1 25
$2.0B
$357.0M
Q4 24
$1.1B
$354.4M
Q3 24
$1.0B
$357.1M
Q2 24
$1.1B
$420.9M
Q1 24
$884.8M
$430.7M
Stockholders' Equity
PTCT
PTCT
UDMY
UDMY
Q4 25
$-205.3M
$210.5M
Q3 25
$-155.8M
$221.8M
Q2 25
$-206.5M
$233.4M
Q1 25
$-185.8M
$209.4M
Q4 24
$-1.1B
$197.4M
Q3 24
$-1.1B
$196.3M
Q2 24
$-980.2M
$252.3M
Q1 24
$-893.9M
$296.5M
Total Assets
PTCT
PTCT
UDMY
UDMY
Q4 25
$2.9B
$617.7M
Q3 25
$2.6B
$618.9M
Q2 25
$2.6B
$644.0M
Q1 25
$2.7B
$639.0M
Q4 24
$1.7B
$605.6M
Q3 24
$1.8B
$608.9M
Q2 24
$1.9B
$671.9M
Q1 24
$1.8B
$708.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PTCT
PTCT
UDMY
UDMY
Operating Cash FlowLast quarter
$-34.3M
$15.5M
Free Cash FlowOCF − Capex
$-36.6M
$15.0M
FCF MarginFCF / Revenue
-22.3%
7.7%
Capex IntensityCapex / Revenue
1.4%
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$702.3M
$81.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PTCT
PTCT
UDMY
UDMY
Q4 25
$-34.3M
$15.5M
Q3 25
$-66.3M
$15.7M
Q2 25
$-58.3M
$44.2M
Q1 25
$870.1M
$12.2M
Q4 24
$-30.0M
$9.6M
Q3 24
$-77.0M
$-6.1M
Q2 24
$-71.5M
$28.6M
Q1 24
$70.8M
$21.0M
Free Cash Flow
PTCT
PTCT
UDMY
UDMY
Q4 25
$-36.6M
$15.0M
Q3 25
$-69.7M
$15.1M
Q2 25
$-59.6M
$41.9M
Q1 25
$868.4M
$9.8M
Q4 24
$-33.8M
$8.4M
Q3 24
$-77.5M
$-6.7M
Q2 24
$-78.8M
$28.2M
Q1 24
$61.2M
$20.8M
FCF Margin
PTCT
PTCT
UDMY
UDMY
Q4 25
-22.3%
7.7%
Q3 25
-33.1%
7.7%
Q2 25
-33.3%
21.0%
Q1 25
73.8%
4.9%
Q4 24
-15.8%
4.2%
Q3 24
-39.4%
-3.4%
Q2 24
-42.2%
14.5%
Q1 24
29.1%
10.6%
Capex Intensity
PTCT
PTCT
UDMY
UDMY
Q4 25
1.4%
0.3%
Q3 25
1.6%
0.3%
Q2 25
0.7%
1.1%
Q1 25
0.1%
1.2%
Q4 24
1.8%
0.6%
Q3 24
0.3%
0.3%
Q2 24
4.0%
0.2%
Q1 24
4.6%
0.1%
Cash Conversion
PTCT
PTCT
UDMY
UDMY
Q4 25
Q3 25
-4.17×
9.58×
Q2 25
7.06×
Q1 25
1.00×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons